Dr. Kumar Discusses Daratumumab in Multiple Myeloma

Shaji K. Kumar, MD
Published: Thursday, May 18, 2017



Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab (Darzalex) in multiple myeloma.

The first monoclonal antibodies have been approved for use in multiple myeloma. Daratumumab, a monoclonal antibody, binds to CD38, which is overexpressed by multiple myeloma cells.

The results seen with daratumumab have been quite striking, says Kumar. There have been 2 large phase III trials, both of which showed adding daratumumab to regularly used regimens improved progression-free survival.
 


Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab (Darzalex) in multiple myeloma.

The first monoclonal antibodies have been approved for use in multiple myeloma. Daratumumab, a monoclonal antibody, binds to CD38, which is overexpressed by multiple myeloma cells.

The results seen with daratumumab have been quite striking, says Kumar. There have been 2 large phase III trials, both of which showed adding daratumumab to regularly used regimens improved progression-free survival.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x